Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Shares Outstanding (Weighted Average) (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Shares Outstanding (Weighted Average) for 5 consecutive years, with $63.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 3.26% to $63.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $63.6 million through Dec 2025, up 3.26% year-over-year, with the annual reading at $63.6 million for FY2025, 3.26% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $63.6 million in Q4 2025 for Protagonist Therapeutics, roughly flat from $63.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $63.6 million in Q4 2025 to a low of $48.8 million in Q1 2022.
  • Historically, Shares Outstanding (Weighted Average) has averaged $57.7 million across 4 years, with a median of $60.9 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): increased 20.33% in 2024 and later grew 3.26% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $49.1 million in 2022, then rose by 15.59% to $56.8 million in 2023, then rose by 8.46% to $61.6 million in 2024, then rose by 3.26% to $63.6 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for PTGX at $63.6 million in Q4 2025, $63.4 million in Q3 2025, and $63.5 million in Q2 2025.